<unk>  (ABT-874) is a human monoclonal antibody being developed by Abbott Laboratories for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. As of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe.
Like ustekinumab, the antibody targets the interleukins 12 and 23.
Briakinumab
Canakinumab
Anakinra
Sarilumab
Nebacumab
Belatacept
Secukinumab
Avelumab